Compound 1477
Identifiers
- Canonical SMILES:
C[C@H]1C[C@H](CCN1Cc1ccccc1-c1ccc(Cl)cc1)N1CCc2c(C1)ncnc2NS(=O)(=O)c1ccc(N[C@H](CCN(C)C)CSc2ccccc2)c(c1)N(=O)=O
- IUPAC name:
N-[7-[(2S)-1-[[2-(4-chlorophenyl)phenyl]methyl]-2-methylpiperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrobenzenesulfonamide
- InChi:
InChI=1S/C44H51ClN8O4S2/c1-31-25-36(20-23-51(31)27-33-9-7-8-12-39(33)32-13-15-34(45)16-14-32)52-24-21-40-42(28-52)46-30-47-44(40)49-59(56,57)38-17-18-41(43(26-38)53(54)55)48-35(19-22-50(2)3)29-58-37-10-5-4-6-11-37/h4-18,26,30-31,35-36,48H,19-25,27-29H2,1-3H3,(H,46,47,49)/t31-,35+,36-/m0/s1
- InChiKey:
UTJLAPPYABGNIH-NUHNATIRSA-N
External links
![]() 168317968 |
External search
![]() |
![]() |
![]() |
![]() |
![]() |
Bibliography (1)
Publication | Name |
---|---|
Karen Miller-Moslin, Bakary-Barry Toure, Michael Scott Visser, Naeem Yusuff, Novartis Ag. . Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer None. | 3 |
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
BCL2-Like / BAX | 7.21 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 854.32 g/mol | |||
HBA | 12 | |||
HBD | 2 | |||
HBA + HBD | 14 | |||
AlogP | 6.88 | |||
TPSA | 139.52 | |||
RB | 15 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Pharmacological data
Bibliography | Name | Target | Competition | Assay type | Assay name | Cell line | Activity type | Activity |
---|---|---|---|---|---|---|---|---|
WO2011029842 | 3 | BCL2 P10415 |
|
Biochemical assay | Surface Plasmon Resonance | pIC50 (half maximal inhibitory concentration, -log10) | 7.21 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.4164 | Navitoclax | DB12340 | |
0.4075 | GDC-0349 | DB13072 | |
0.4000 | Sulfaisodimidine | DB13283 | |
0.3933 | Presatovir | DB12165 | |
0.3743 | Sparsentan | DB12548 | |
0.3720 | Quinupristin | DB01369 | |
0.3718 | 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine | DB07585 | |
0.3712 | Venetoclax | DB11581 | |
0.3699 | N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOTHIAZIN-4-YL]ETHYL}ACETAMIDE | DB06899 | |
0.3684 | Tianeptine | DB09289 | |
0.3664 | PF-03814735 | DB13059 | |
0.3636 | N-(2-(((5-CHLORO-2-PYRIDINYL)AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE | DB07800 | |
0.3604 | Lenacapavir | DB15673 | |
0.3586 | (3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE | DB07666 | |
0.3584 | Tasosartan | DB01349 |